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Treatments for glioblastoma multiforme and invasive ductal carcinoma involve 
surgical resection and adjuvant or concurrent targeted therapies.  The goal of the 
secondary treatment is to reduce the cancer cells in the resection margin and other areas 
of suspected involvement.  Photochemical internalization is a targeted therapy using light 
to activate photosensitizers embedded in cellular structures to improve the delivery of 
macromolecules within the cell.   
 In a previous study, optimized treatment parameters including radiant exposure, 
and irradiance, concentration of AlPcS(2a), temperature, and the concentration of 
bleomycin were determined for human ACBT glioma multicell spheroids.  The current 
study investigates the effectiveness of the ACBT–optimized concurrent PCI/hyperthermia 
treatment for F98 rat glioma and MCF-7 human invasive ductal carcinoma spheroids.  
The combination of photochemical internalization and hyperthermia was shown to be 
more effective than either treatment modality alone and, in all cases, the combined 
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1.1 Brain Cancer 
The central nervous system (CNS) is associated with several types of benign and 
malignant tumors.  Each year, approximately 35,000 Americans are diagnosed with 
primary brain tumors. Of those 35,000 new diagnoses just over 18,000 are malignant 
brain tumors which account for approximately 2% of all cancers in the United States and 
nearly 13,000 deaths per year (CBTRUS).  
CNS tumors in pediatric patients are 50% more likely to be malignant when 
compared to adults (Khoshnevisan 2012). The central brain tumor registry of the United 
States (CBTRUS) estimates that 1 in every 1300 children will develop a primary brain 
tumor by age 20 (CBTRUS 1998). The incidence rate has increased from 5.85 per 
100,000 person-years in 1975 to 6.4 per 100,000 person-years in 2003 (Chandana et al. 
2008).   
Unfortunately, it is much more difficult to treat primary and secondary malignant 
CNS tumors as compared to benign CNS tumors due to the lack of effective treatments.  
In the past decade, however, advances in several fields including stem cell biology, 
genomic medicine and molecular biology have revolutionized the understanding of brain 
tumorigenesis. These advancements have led to many new therapies that target molecular 
processes in primary malignant CNS tumors (Khoshnevisan 2012).  
 The most frequent primary brain tumor is a glioma.  Gliomas account for 49% of 
primary brain tumors (Wrensch et al. 2002). 
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Of the various central nervous system malignancies glioblastoma multiforme 
(GBM; Figure 1) has a very poor prognosis second only to brain stem gliomas. 
Improvements in the standard of care over the past 7 years have led to only a minor 
increase in the median survival time for patients after diagnosis from 10 to 14 months. 
Current treatments include surgical resection of the tumor followed by various concurrent 
or subsequent treatments such as radiosurgery, chemo-radiotherapy and anti-angiogenic 
therapy (Van Meir et al. 2010). The goal of subsequent treatments is to eliminate the 
malignant cells residing in the margin surrounding the resection cavity thereby reducing 
recurrence of the malignant glioma (Angell-Petersen et al. 2006) (Hirschberg et al. 2004). 
 
Figure 1. T1-weighted post-contrast magnetic resonance images of GBM (a) pre- and (b) 
post-tumor resection. (Lacroix et al. 2001)  
 
Animal tumor models have been used extensively to determine the efficacy of 
emerging therapies.  In the 1970’s it was discovered that intravenous injections of N-




reproducible CNS tumors in adult rats. Since the mid 1970’s rat brain tumor models have 
been used extensively for this purpose.  Although these animal models are useful in 
evaluating treatment methods, existing models cannot exactly simulate human 
glioblastoma multiforme or anaplastic astrocytomas (Barth and Kaur 2009). 
There is a general consensus outlining the criteria that must be met in order for a 
brain tumor model to be considered valid. The criteria are as follows “(1) They should be 
derived from glial cells; (2) it should be possible to grow and clone them in vitro as 
continuous cell lines and propagate them in vivo by serial transplantation; (3) tumor 
growth rates should be predictable and reproducible; (4) the tumors should have glioma-
like growth characteristics within the brain including neovascularization, alteration of the 
blood-brain barrier (BBB), an invasive pattern of growth, and lack of encapsulation; (5) 
host survival time following intracranial tumor implantation should be of sufficient 
duration to permit therapy and determination of efficacy; (6) for therapy studies, the 
tumors should be either non or weakly immunogenic in syngeneic hosts; (7) they should 
not grow into the epidural space or extend beyond the brain and finally, (8) their response 
or lack thereof to conventional treatment should be predictive of the response in human 
brain tumors,” (Barth and Kaur 2009). 
 
1.2 F98 Cell Line 
This study investigates various treatments on the F98 rat glioma as GBM model. 
The F98 glioma (ATCC # CRL-2397) was originally cultured from a subcutaneous tumor 
on a male Fischer rat. F98 gliomas behave similarly to human glioblastomas exhibiting 
low immunogenicity, invasive growth patterns and overexpression of similar genes. F98 
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cells have also been used to produce brainstem tumors in Fischer rats with similar 
histopathological and radiobiological characteristics of primary human brainstem tumors. 
Because of the characteristics of the F98 glioma it has been used extensively as a brain 
tumor model in experimental neuro-oncology for pre-clinical testing of therapies (Barth 
and Kaur 2009). 
 
Table 1. Rat brain tumor models (Barth and Kaur 2009) 
 
The F98 glioma is composed of two different shaped cells. Spindle-shaped cells 
with fusiform nuclei make up the majority while polygonal cells with oval nuclei make 
up the minority of the composition.  The tumor mass is surrounded by pools of tumor 
cells that have extended various distances into the normal brain tissue (Barth and Kaur 
2009).   
The F98 glioma shares several traits with the human GBM including the 
overexpression of PDGFβ and Ras, and increased expression of EGFR, cyclin D1, cyclin 
D2 and Rb when compared to rat astrocytes (Sibenaller et al. 2005). Other characteristics 
of the F98 glioma include decreased expression of BRCA1 and the lack of BRCA1 foci 
induced by radiation and cisplatin (Bencokova et al. 2008). F98 gliomas exhibit necrotic 
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cores, non-glomeruloid neovascular proliferation and, like human GBM, are 
characterized by extensive infiltration into normal brain (Figure 2) (Mathieu et al. 2007). 
Studies have shown that the F98 glioma is radio-resistant, probably due to its functionally 
impaired BRCA1 status (Bencokova et al. 2008), making it a model for evaluating the 
efficacy of combination therapies. The F98 model can be used to determine which 
therapies should go on to further clinical trials and which therapies would likely have 
little to no effect and should be discarded. 
 
Figure 2. Hematoxyllin and Eosin-stained histological section of Fischer rat brain 
illustrating the diffuse and infiltrative nature of F98 tumor cells. (Barth and Kaur 2009). 
   
1.3 Breast Cancer 
The second type of cancer used for evaluating treatments in this study is breast 
cancer. According to the Center for Disease Control (CDC), breast cancer is the second 
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most common cancer in women and one of the leading causes of cancer related death 
among women.  The most recent statistics show that in 2009 over 200,000 women in the 
United States were diagnosed with breast cancer and over 40,000 women in the United 
States died from breast cancer. One in every eight women will be diagnosed with breast 
cancer in her lifetime (U.S. Cancer Statistics Working Group 2013).  
Accounting for about 80% of all breast cancers, invasive ductal carcinoma is the 
most common type of breast cancer.  This infiltrating cancer begins in the milk ducts 
which act as a connection between the milk producing lobules and the nipple.  From there 
it invades the other areas of the breast and possibly the lymph nodes and other areas of 
the body.  This type of cancer is more common among older women with two thirds of 
reported cases being in women age 55 and older.  On average in the United States there 
are over 180,000 cases of invasive breast cancer each year. The signs and symptoms 
associated with ductal carcinoma include: swelling or pain in the breast region, a lump in 
the underarm area or thickening of the breast skin.  Diagnosis is performed by physical 
examination and the use of imaging modalities such as mammography, ultrasound and 
MRI. Biopsies are performed for any suspicious findings from the image results. Staging 
for ductal carcinoma is based on tumor size, extent of the spread to the lymph nodes and 
the extent of spread to other parts of the body.  
Treatment options for breast cancer are based on the stage and type of the cancer.  
Stage 0 is classified as in situ and diagnosis at stage 0 has a 100% five year survival rate.  
Patients with stage 0 lobular carcinoma are advised to undergo rigorous breast cancer 
surveillance (National Comprehensive Cancer Network 2009).   Ductal carcinoma in situ 
(DCIS) is more serious and unlike lobular carcinoma in situ can progress to invasive 
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breast cancer.  Ductal Carcinoma has a 100% survival rate if diagnosed in situ. Treatment 
of DCIS involves breast conserving surgery or mastectomy depending on the extent of 
the disease and radiation therapy (Maughan et al. 2010).   
As the stage of the breast cancer advances from stage I to stage IV the five year 
survival rate decreases from 98 to 23.4% respectively.  Treatment for later stage breast 
cancer involves evaluation of lymph nodes by dissection, breast conserving surgery or 
mastectomy, radiation therapy and adjuvant therapies depending on the hormone 
receptors and the expression of ERBB2 (Maughan et al. 2010). Radiation therapy 
following breast conserving surgery has shown a significant reduction of the five year 
local recurrence rate and an apparent decrease in the 15 year mortality risk (Clarke et al. 
2005).  Adjuvant systemic therapies such as chemotherapy, endocrine therapy, and tissue 
targeted therapies are most beneficial to patients with node-positive disease.  These 
therapies are able to substantially reduce cancer recurrence by enhancing local therapies 
such as surgery, radiotherapy or both (National Comprehensive Cancer Network 2009). 
Induction systemic therapies are performed on patients with locally advanced breast 
cancer.  Induction chemotherapy is able to facilitate the preoperative reduction of the 
tumor by more than 50% for 75% of patients thus allowing for breast conserving surgery 
(Mauri et al. 2005). New and developing treatment options involve targeted therapies 
which are specifically directed toward the tumor characteristics.   
 
1.4 MCF-7 Cell Line 
The MCF-7 cell line was used in this study as an invasive ductal carcinoma 
model. The MCF-7 breast cancer cell line was originally acquired from a 69 year old 
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Caucasian woman in 1970.  This cell line is particularly relevant since it was the first 
mammary cell line that was capable of surviving more than a few months.  
 MCF-7 is one of three breast cancer cell lines (BCCL) that account for 80% of the 
35,000 publications involving BCCL. In the last decade MCF-7 has been the most used 
appearing in 53% of all journal articles that mention BCCL. It was acquired from pleural 
effusion of an invasive ductal carcinoma (Soule et al. 1973). This method facilitates the 
recovery and growth of the cell line easier than extracting cells directly from tumors or 
metastasis due to the large number of isolated tumor cells and low yield of contaminant 
cells. The estrogen receptor (ER) and progesterone receptor (PgR) status of the MCF-7 
cell line is ER+ and PgR+ (Bana and Bagrel 2011).  
 Extensive studies with the MCF-7 line over the past 40 years has led to the 
establishment of complete genetic and proteinic profiles allowing this cell line to become 
a reference model in the field of breast cancer research (Bana and Bagrel 2011).  
 
1.5 Monolayer vs. Multicellular Tumor Spheroids 
 Two-dimensional cultures have been used as in vitro models for cancer research 
for many years.  There are several advantages to monolayers including ease of set up and 
good viability of cells.  However being one of the simplest models, they lack the 
complexity that better represents solid tumors.  Transport is limited in 2D models due to 
the lack of structure.  Cells often exhibit characteristics when cultured in a monolayer 
that differ from their in vivo counterparts (Bissel 1981).  Organ cultures are also a useful 
tool for modeling cancer due to the fact that they have an already established tumor 
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microenvironment, including cell-cell interactions and cell-matrix interactions. They are 
however difficult to obtain and exhibit poor viability in culture (Kim 2005).   
 Multicellular tumor spheroids (MCTS) were developed to bridge the gap between 
monolayer cultures and animal models. They include cell-cell interactions and extra-
cellular matrix interactions that are vital to the growth and propagation of tumors. The 
surface and intracellular junctions of an MCF-7 spheroid are shown in Figure 3. 
 
Figure 3. MCF-7 spheroid, left (scale bar: 100 µm); intracellular junctions indicated by 
the arrows, right (scale bar: 5 µm). (Ho et al. 2012) 
 
Spheroids were developed for cancer research to better understand the effects of 
radiation and chemotherapeutic agents on 3D cultures (Wheldon 1994) (Yuhas et al. 
1978).  There are several advantages to 3D cultures compared to monolayers.  There is a 
higher degree of cellular heterogeneity in 3D cultures compared to the homogeneity of 
monolayers.  The 3D structure presents obstacles in nutrient transport which creates 
cellular proliferation gradients.  Regions that are amply supplied with O2 have 
proliferating cells adjacent to microvessels.  In regions where nutrient diffusion and 
waste removal is limited, the cell cycle times are increased. This environment produces 
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quiescent cells that are at rest in G0 phase but remain clonogenic. Towards the center of 
the spheroid, non-proliferating cells can be found (Mueller-Kleiser 1987).  This 
proliferation gradient sets spheroids apart from monolayers and resembles the volume 
growth kinetics of solid tumors. The various regions of the multicellular spheroid are 
shown in Figure 4. 
 
  Figure 4. Regions and gradients in MCTS. (Lin and Chang 2008) 
 
Mueller-Kleiser observed three general phases of multicellular spheroid growth as 
shown in Figure 5. In the initial phase there is exponential growth as the cells proliferate 
until a diameter of 50-200 µm is achieved. After this initial growth phase the cell cycle 
distribution changes with an increase in non-proliferating cells (Durand and Sutherland 
1975).  This, along with the peripheral cell detachment greatly reduces the number of 
proliferating cells.  The second phase exhibits a linear increase in the spheroid diameter 
versus time.  Volume increase is significantly impaired in the third growth phase as the 
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spheroids reach a maximum diameter ranging from 1 – 4 mm (Sutherland and Durand 
1976). Spheroids will maintain this diameter indefinitely without vascularization which 
leads to exponential growth. After vascularization, growth saturation is possible assuming 
the disease doesn’t terminate the host first (Steele 1977). These growth phases resemble 
the avascular growth of tumors and show that cellular aggregates can remain dormant 
until vascularization induces exponential growth. 
 
Figure 5. Tumor growth curve. (Mueller-Kleiser 1987) 
 
3D cultures exhibit increased resistance to treatments and show similar drug 
sensitivity patterns to in vivo tumors (Ohmori et al. 1998). As cells begin to form into 3D 
spheroids their cell shape and environment change mimicking that of glandular tumors as 
they transition from early to intermediate adenoma stages (Rak et al. 1995). 
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 The extra cellular matrix (ECM) is much more extensive in spheroids as 
compared to monolayers. Monolayers have a reduced ability or even inability to 
synthesize the materials required for the extracellular matrix.  Conversely, spheroids 
retain much of the structural and functional differentiation of solid tumors (Mueller-
Kleiser 1987).  The ECM along with cell to cell interactions can have an impact on the 
distribution and function of drugs and physiological factors which can result in cellular 
growth, death and differentiation (Kim 2005).   
 In order to use MCTS for various applications they must be easily and reliably 
reproduced.  There are several methods for MCTS generation with associated advantages 
and disadvantages.  Factors that should be considered when deciding upon a generation 
technique should include: MCTS size uniformity, effect on cellular physiology, 
convenience and efficiency (Lin and Chang 2008). 
 
1.6 Targeted Therapies 
 MCTS can be used to evaluate targeted therapies. Both cancers included in 
this study have surgical resection as the primary mode of treatment with secondary 
concurrent or adjuvant targeted therapies.  
There has been increased interest in recent years in targeted therapies involving 
the clinical use of macromolecular drugs, such as cytotoxic agents.  This is partly due to 
the advances in production technology and to a better understanding of the utilization of 
these types of drugs. Macromolecular drugs have the advantage of being much more 
specific for therapeutic targets than traditional drugs (Hogset et al. 2004). Many of the 
intended targets for specific drug therapies are intracellular and therefore difficult for the 
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macromolecule to reach.  This lends to the need for the development of technologies that 
allow for the delivery of such drugs into the target cells.  For cancer therapy, specificity is 
very important in determining the therapeutic outcome.   
 The structure of macromolecular drugs prevents them from passing directly 
through the plasma membrane making it especially difficult for them to reach specific 
intracellular targets.  These drugs usually enter the cell through the process of 
endocytosis.  As the drug is engulfed by the cell it resides inside endocytic vesicles such 
as endosomes.  Eventually the drug is degraded and loses its ability to cause a biological 
effect on the intended target. In order to obtain an effect from the drug there must be a 
means of escape from the endosomal membrane before degradation in lysosomes. 
 
1.7 Photodynamic Therapy (PDT) 
 The idea of using light and chemicals to cause cytotoxic effects is not new.  In 
1900 Oscar Raab showed that the combination of acridine and specific wavelengths of 
light could prove lethal for a species of Paramecium. In modern PDT, light activates a 
photosensitizer, both non-toxic components individually, which in turn transfers energy 
to oxygen creating a reactive oxygen species (ROS). This process induces cytotoxic 
effects (Figure 6).  Direct cytotoxicity, inflammatory and immunological responses and 
vascular damage contribute to the therapeutic effect of PDT. These mechanisms will be 
discussed at a later point (Dolmans et al. 2003).  
 The photosensitizer is the first component in PDT.  The clinically relevant 
properties that make a suitable photosensitizer will be discussed.  Photosensitizers for the 
clinical setting and the related metabolites should be non-toxic, and non-carcinogenic.  
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The photosensitizer should exhibit reliable activation by the appropriate light wavelength 
and minimal activation by other wavelengths. It is crucial that the photosensitizer 
accumulates in the proper tissues and localize in the desired targets.  Depending on the 
intracellular localization, the damage caused by the photoreaction could induce various 
responses and mechanisms of cell death.  The solubility of the photosensitizer will 
determine how easily it travels through the body.  The absorption spectrum of the 
photosensitizer determines the wavelength of the incident light which affects the depth in 
tissue that can be treated.  Lastly, a photosensitizer should not prevent or restrict other 
treatments that are used in conjunction with PDT such as radiotherapy, chemotherapy or 
surgery (Allison et al. 2004).  
Photodynamic therapy has been approved by the FDA for the treatment of 
esophageal cancer and non-small cell lung cancer using the photosensitizing agent 
porfimer sodium (Photofrin®). Clinical trials are currently underway to evaluate PDT for 
cancers involving the brain, skin, prostate, cervix and peritoneal cavity (NCI 2011).  
The photosensitizing agent can be administered intravenously or topically 
depending on the need. It is important to remember that the method used to administer 
the photosensitizer greatly affects the bio-distribution of the agent. The effects of PDT 
can then be regulated based on the timing of the light exposure and the bio-distribution of 
the molecule over time (Dolmans et al. 2003). The process of activation involves the 
absorption of light to raise the photosensitizer from the ground state to a very short, 
excited singlet state and then to a longer excited triplet state (Henderson and Dougherty 
1992).   
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Figure 6. Excitation of the photosensitizer resulting in the production of free radicals in 
the presence of oxygen. (Dolmans et al. 2003) 
 
The excited triplet state then undergoes a type I or II reaction (Figure 7).  In type I 
reactions a hydrogen atom is transferred from the excited photosensitizer to a substrate 
forming radicals which then interact with oxygen to produce oxygenated products.  A 
type II reaction involves the formation of singlet oxygen from the direct energy transfer 
between the excited photosensitizer and oxygen. This oxygen dependence prevents 
photosensitization in oxygen depleted regions. The rate of occurrence of type I and II 
reactions is dependent on several factors including the photosensitizer being used, the 
binding affinity of the photosensitizer to the substrate and the relative concentrations of 








Figure 7. Type I and Type II reactions. (Dolmans et al. 2003) 
 
The damage caused by the ROS is local due to its high reactivity and relatively short half-
life of <0.04 µs. Studies have shown the radius of action of singlet oxygen is <0.02 µm.  
The light exposure dose and dose rate in combination with the type of photosensitizer, its 
localization and the tissue oxygen concentration affect the extent of photodamage and 
resultant cytotoxicity (Moan and Berg 1991).   
PDT is able to induce tumor damage through three primary mechanisms: direct 
cytotoxicity, vascular damage and activation of an immunological response (Dougherty 
1998).  
Direct cytotoxicity is a result of the damage caused by the generation of ROS. 
The difficulty with this mechanism is that it is directly related to the localization of the 
photosensitizer. It has been shown that, in cases of intravenously administered 
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photosensitizer, cytotoxicity decreases with increasing distance between tumor cells and 
the vasculature (assuming a homogenous distribution of the sensitizer and readily 
available oxygen within the tumor). In order to minimize the rapid depletion of oxygen in 
the tumor, and thus the diminution of the direct cytotoxic effect, fractionation methods 
and/or low light fluence rates can be used to facilitate re-oxygenation (Messmann 1995).  
Alternatively, PDT can cause a therapeutic effect by damaging the tumor 
vasculature.  This in effect cuts off the nutrient supply to the tumor.  Several studies have 
been published that indicate microvascular collapse, vasoconstriction and thrombus 
formation leading to hypoxia and ultimately inhibition of tumor growth (Henderson and 
Fingar 1987) (Chen et al. 1996) (Dolmans 2002). 
Lastly, PDT has been shown to cause an immunological response resulting in 
tumor damage. Post-PDT treatment analysis in the early 1990’s showed an influx of 
leukocytes and lymphocytes into the treatment region indicating an immunological 
response. Researchers have found that murine vaccinations prepared from the lysate of 
tumor cells treated with PDT are more effective than those prepared from the lysates of 
tumor cells treated with ionizing or ultraviolet radiation (Gollnick et al. 2002). 
Tumors exhibit several properties that increase the preferential uptake and 
retention of photosensitizers compared with surrounding tissues including: poor 







1.8 Aluminum Phthalocyanine Disulfonate 
 Aluminum Phthalocyanine Disulfonate [AlPcS(2a)] is a second generation 
photosensitizer used for PDT. The structure is shown in Figure 8. The central metal ion 
determines the photochemical properties of phthalocyanines.  
 
Figure 8. Aluminum Phthalocyanine Disulfonate structure (Hogset et al. 2004). 
 
For this reason it is important to use a metal that has a high triplet yield and fluorescence 
yield: both, zinc and aluminum exhibit these properties (Ambroz et al. 1991).  AlPcS(2a) 
exhibits several advantages over early photosensitizers used in PDT including water 
solubility and its high absorbance in the red part of the visible spectrum (675nm) makes it 
ideally suited for in vivo use due to the high penetrance of red light in biological tissues. 







Figure 9. AlPcS(2a) absorption spectrum (Prasmickaite et al. 2001). 
 
Light of this wavelength is able to penetrate almost twice as deep into tissue as the 630 
nm light used to activate photofrin II (PII).  Another advantage involves the relatively 
low absorbance in other regions of the solar spectrum, minimizing the risk of 
photoreaction in patients after treatment (Chan et al. 1997).   
Localization of the photosensitizer to the tumor, specific location inside the cell 
and the ability to induce tissue damage are important characterisitics of photosensitizers. 
Studies have shown that, as the degree of sulphonation increases, the ability to localize to 
the tumor increases but the ability to induce necrosis decreases (Berg et al. 1989). The 
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two sulfonate groups on the adjecent phthalate rings lend to the amphiphicity of 
AlPcS(2a) allowing it to primarily localize in the membranes of endocytic vesicles (Berg 
and Moan 1994). The uptake properties of AlPcS(2a) determined in vitro and the tumor 
necrosis properties from in vivo studies have made AlPcS(2a) a possible clinical 
alternative to Photofrin (Witjes et al. 1996) 
Precautions must be taken when working with AlPcS(2a).  Although it is a 
relatively stable photosensitizer, it is important to avoid light which could induce damage 
to the photosensitizer.  Also, long periods of storage can cause aggregation which reduces 
the efficacy of the photosensitizer (Prasmickaite et al. 2001). 
 
1.9 Photochemical Internalization (PCI) 
PCI is a technology that enhances the efficacy of several different classes of 
molecules by allowing for site specific drug delivery. PCI is based on studies that showed 
when photosensitized cells were exposed to light the photosensitizer was released into the 
cytosol due to permeabilization of the vesicle (Figure 10).  Lysosomal enzyme activities 
were also observed in substantial amounts in the cytosol after exposure to light 
demonstrating that other molecules within the lysosomes are released into the cytosol 
(Berg and Moan 1994).  
This delivery mechanism is possible without causing excess damage to the cell 
and minimally affecting the biological activity of the released molecule.  The 
photochemical damage to the enveloped molecule varies with its location relative to the 
photosensitizer.  The photosensitizer accumulates in the endocytic membrane and the O2 
molecules (singlet molecular oxygen) that are produced from the photochemical reaction 
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have a very short range of action. The specific mechanism that causes the endocytic 
membrane to rupture after photochemical excitation is not known. Belzacq et al. (2001) 
and Zavodnik et al. (2002) have shown for mitochondrial and erythrocyte membranes 
respectively that damage to membrane proteins may contribute more than oxidation of 
membrane lipids to the mechanism causing membrane rupture. 
 
Figure 10. Photochemical internalization process. The drug “D” enters the cell by 
endocytosis. Light activation of the photosensitizer “S” disrupts the endosomal 
membrane releasing the drug into the cytosol thus preventing degredation in the 
lysosome. (Norum et al. 2009) 
 
 
Another method of performing PCI has come to be known as “light first” PCI.  
This is similar to the standard mode of PCI (Figure 10) with the alteration of performing 
the illumination and excitation of the photosensitizer before treatment with the molecule 
to be internalized.  Again the mechanism of “light first” PCI is not completely understood 
but it has been hypothesized that new vesicles containing the macromolecule combine 
with vesicles that have been previously damaged by the photochemical reaction and the 
resultant vesicle has an imperfect structure that leaks the macromolecule into the cytosol 




Figure 11. “Light first” PCI process. Light activation of the photosensitizer “S” disrutps 
endosomal membranes. Later, the drug “G” enters the cell by endocytosis and is released 
into the cytosol when previously damaged endosomes fuse with endosomes containing 
the drug. (Hogset et al. 2004) 
 
 Various studies have indicated the ability of PCI to induce biological effects due 
to the endosomal release of several different molecules including: ribozymes, plant 
protein toxins, oligodeoxynucleotides, immunotoxins, and genes using viral and non-viral 
vectors (Berg et al. 1999) (Selbo et al. 2000) (Hogset et al. 2000).  
 The optimal light dose for the PCI effect will vary depending upon the cell type. 
Different cell types will exhibit varying levels of photosensitizer uptake, sensitivity to the 
cytotoxic effects produced by the photochemical reaction and different concentrations of 
the photosensitizer in the endosomal membranes (Hogset et al. 2004). In determining the 
optimal light dose, one must consider the desired end result.  While increasing the light 
dose has been shown to increase the drug delivery effect, it also increases the cytotoxic 
effects of the photochemical treatment.  For various cancer therapies in which the desired 
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goal is to kill all the cells in a specific area, PCI is able to produce a substantial effect at 
lower light doses than traditional PDT.  This enables the therapeutic treatment of much 
deeper tissues than is possible with PDT.  For treatments with a desired effect of treating 
target cells that are intermixed with normal cells and using a drug that acts on the target 
cells; the lower light doses used for PCI are able to aid the release of the drug while 
minimizing the cytotoxic effects of the photochemical treatment (Hogset et al. 2004).   
 Just as with any therapeutic modality, there are several advantages and 
disadvantages to PCI.  Experiments have shown that PCI is effective at delivering 
molecules ranging from very small adenoviral particles to large macromolecules giving 
the technology great flexibility.  By increasing the efficiency of specific drugs, PCI is 
able to maintain a similar biological effect while reducing the dose administered.  This 
can significantly reduce the observed side effects of drug therapy.  Another advantage of 
PCI is its ability to damage non-dividing cells, such as resting malignant cells which 
directly affect the outcome of the cancer therapy.  Traditional radiation therapy is far less 
efficient at killing quiescent cells. An obvious disadvantage is damage to the enveloped 
molecule as a result of the photochemical reaction. Lipid-like complexes will localize 
closer to the membrane containing the photosensitizer resulting in a higher probability of 
damage.  The “light first” mode could be performed to induce the photochemical 
reactions prior to the introduction of the molecule thus potentially minimizing damage to 







The chemotherapeutic agent used in this study is the glycopeptide antiobiotic bleomycin 
(Figure 12). Although bleomycin (BLM) actually refers to a family of structurally similar 
compounds produced by various Streptomyces the chemotherapeutic forms consist 
mainly of bleomycin A2 and B2 (Barber et al. 1981). The several structures of bleomycin 
differ in the cationic side chain and at the bithiazole moiety.   
In order to become activated and initiate DNA damage, the bleomycins require a 
reducing agent, a reduced metal and molecular oxygen. Several pathways have been 
proposed to explain the mechanism of damage to the DNA and they depend on the 
oxygen concentration (Strekowski and Wilson 2007). Hoehn et al. (2001) have proposed 
a double strand cleavage by a single BLM molecule. 
In the clinical setting BLM has been approved by the FDA for use alone or in 
combination with other drugs as palliative treatment of Hodgkin lymphoma, squamous 
cell carcinoma of the head, neck and cervix, testicular cancer and to treat malignant 
pleural effusion (NCI Drug Information).  BLM is used extensively in the research setting 












Figure 12. Structure of bleomycins. (Barber et al. 1981) 
 
1.11 Hyperthermia 
The combination of brain tumor treatment modalities, such as photodynamic 
therapy [PDT], and hyperthermia have shown increased tumor control in a number of in 
vitro and animal studies (Hirschberg et al. 2004).   
Treatments under hyperthermic conditions are already in clinical use.  Exposure 
to hyperthermic conditions can cause cell death, inhibit repair of sub-lethal damage and 
increase the sensitivity of hypoxic cells to radiation.  The extent of the effects of 
hyperthermia on tumor cells depends on the temperature and length of time of exposure 
(Hirschberg et al. 2004).  Tumor permeability to macromolecules has been shown to 
increase in the presence of heating.   
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Studies have shown that hyperthermia can greatly affect the ability of proteins 
and, in some cases, it can inhibit protein synthesis (Fuhr 1974) (Henle and Leeper 1979). 
One example of this is the enhancement of bleomycin treatments by hyperthermia. 
Studies have demonstrated that this enhancement is not due to increased bleomycin 
uptake in heat treated cells (Braun and Hahn 1975). Bleomycin hydrolase is an enzyme 
that degrades bleomycin and is present in higher concentrations in bleomycin resistant 
cells (Miyaki et al. 1975). Typically, bleomycin survival curves are biphasic showing an 
initial induction of resistance which decays following the removal of the bleomycin.  
Hyperthermia is able to alter the function of the bleomycin hydrolase and effectively 
remove the bleomycin resistant phase in the survival curve. Heat treated cells therefore 
have a reduced bleomycin inactivation ability (Lin et al. 1983). The enhancement of the 
bleomycin cytotoxic effect by hyperthermia is well documented in several in vitro and in 
vivo studies (Magin et al. 1979) (Meyn et al. 1979) (Miyaki et al. 1975). 
 
1.12 Scope of work 
The purpose of this thesis research is to investigate the effect of combined 
AlPcS(2a) – mediated PCI + HT on multicellular tumor spheroids. Earlier studies have 
shown a synergistic effect of PCI and bleomycin over PDT or bleomycin alone. In all 
cases, treatment efficacy will be evaluated by comparing the growth kinetics and viability 
of multicellular tumor spheroids after HT, AlPcS(2a) – mediated PCI and AlPcS(2a) – 
mediated PCI + HT treatments. 
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Hypothesis – A combined AlPcS(2a) – mediated PCI of bleomcyin + HT 
treatment will show greater tumor control than would be expected from the addition of 































MATERIALS AND METHODS 
2.1 Cell Lines 
Experimental trials were performed on the F98 and MCF-7 cell lines at the 
University of Nevada, Las Vegas. Both cell lines were cultured in Dulbecco’s Modified 
Eagle’s Medium [DMEM] (Life Technologies, Carlsbad, CA) with high glucose [1X] 
and supplemented with 10% heat inactivated-fetal bovine serum [FBS], 25mM HEPES 
buffer and 5 mL Pen-Strep (10,000 Units/mL Penicillin and 10,000 µg/mL 
Streptomycin). During experimentation the cell lines were maintained at 37ºC, 95% 
humidity and 5% CO2 in T-25 BD Falcon tissue culture vented cap flasks. The cells were 
sub-cultured using the following protocol.  The cellular confluency was determined using 
light microscopy. The culture medium was then discarded and the cells were washed by 
adding 5 mL phosphate buffered saline [PBS] (Life Technologies, Carlsbad, CA) to the 
flask and then discarding the solution. One mL of 0.25% Trypsin-EDTA solution was 
added to the flask and allowed to sit for 5 minutes. This allows enough time for the 
proteolytic enzyme to aid the detachment of the cells from the flask. After the cell layer 
dispersed and the cells detached, 4 mL of DMEM was added to the flask and the cells 
were aspirated by gently pipetting. Depending on the confluence of the original cell 
suspension, 0.5 mL to 1.0 mL aliquots of the sub-cultured cell suspension were added to 
a new culture flask with additional DMEM to bring the total solution volume to 5 mL. 





2.2 Multicellular Tumor Spheroid Formation 
The multicellular tumor spheroids were formed based on a rapid generation 
technique (Ivascu and Kubbies 2006). Immediately after sub-culturing, 0.1 mL of the cell 
suspension was added to 9.9 mL of IsoFlow Sheath Fluid (Beckman Coulter Inc., Brea, 
CA) in a Coulter cup and the number of cells was counted in the Model Z2 Beckman 
Coulter Particle Count and Size Analyzer. The cell count was used to determine the 
cellular concentration in cells/mL.  DMEM was added to dilute the concentration of the 
cellular suspension to 32,000 cells per mL. Then 0.2 mL of the cellular suspension 
(~6400 cells) was placed in each well of an ultra-low attachment round bottom 96 well 
plate coated with matrigel. The plate was then centrifuged at 1,000 x g for 10 minutes in 
a Heraus Megafuge 16 (Thermo Scientific, Waltham, MA).  The resulting spheroids were 
incubated at 37ºC, 95% humidity and 5% CO2 for 48 hours. This allowed enough time for 
the 3D formation of the spheroid. 
 
2.3 Photodynamic Therapy 
After 48 hours the spheroids were visually inspected and then transferred to 35 x 
10 mm petri dishes for treatment. AlPcS(2a) was used as a photosensitizer for all 
experiments. The stock AlPcS(2a)  solution was diluted in DMEM to 1 µg/mL and  2 mL 
of the diluted AlPcS(2a) solution was added to each treatment group. This was done in 
minimal lighting to prevent premature activation of the AlPcS(2a).  The treatment groups 
were then incubated at 37ºC, 95% humidity and 5% CO2.  After 18 hours the treatment 
groups were washed with DMEM to remove excess AlPcS(2a) and placed in new 
medium. The treatment groups were then incubated for 4 hours to allow the 
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internalization of the photosensitizer and minimize the damage induced in the plasma 
membrane.    
 
2.4 Photochemical Internalization 
After washing the treatment groups to remove excess AlPcS(2a), the PCI groups 
were then treated using BLM. The stock BLM solution was diluted in DMEM to 0.25 
µg/mL and 2 mL of the diluted BLM solution was added to the petri dishes containing 
the PCI groups.  After 4 hours of incubation at 37ºC, 95% humidity and 5% CO2, the PCI 
groups were washed with DMEM to remove excess BLM and placed in new medium. 
 
2.5 Hyperthermia 
All groups treated with HT were placed in an oven at 42ºC for 40 minutes.  All 
non-HT groups were placed in the same oven for 40 minutes at 37ºC. The laser therapy 
was performed while the spheroids were in the oven. 
Laser therapy was performed using a photodiode laser (670 nm) coupled to a 200 
µm diameter optical fiber containing a microlens.  PCI and PDT groups were treated with 
radiant exposures of 1, 1.5 and 2.5 J/cm
2
 @ an irradiance of 5 mW/cm
2
. The treated 
spheroids were then transferred into 48 well plates coated with 0.25 mL agarose-
(2X)DMEM solution and 0.75 mL DMEM.    
 
2.6 Measurements 
Spheroid size was determined by taking the average of two orthogonal diameter 
measurements using a light microscope with a calibrated micrometer on the eyepiece. 
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F98 spheroid growth was recorded twice weekly for one month resulting in nine 
measurements. MCF-7 spheroid growth was recorded twice weekly for 5 measurements.  
This was due to the fact that after the MCF-7 spheroids reached a certain size they 
became non-spheroidal and measurements were no longer feasible. This is explained in 
more detail in the MCF-7 results section. After each measurement, the growth medium 
was renewed by removing 0.4 mL of medium from each well and replacing it with 0.4 
mL fresh DMEM. 
 
2.7 Statistical analysis 
 Data analysis was performed in Microsoft Excel.  Three trials were performed for 
each treatment group consisting of approximately 16 spheroids. The standard error was 
used in creating error bars. Statistical significance was determined using the Student’s T-
test. In order to determine the degree of interaction between the combined PCI+HT 
treatment compared with the individual PCI and HT treatments the following equation 
was used (Drewinko et al. 1976). 
              
           
        
                                               (Eq. 1) 
 
The numerator includes the product of the surviving fractions (SF) of the individual 
treatments separately and the denominator includes the surviving fraction of the 
combined treatment. A value of α = 1 indicates an additive effect.  A value of α < 1 or α 









3.1 F98 Spheroid Viability 
 F98 rat glioma spheroid viability is shown in Figure 13. No cytotoxic effects were 
observed for spheroids exposed to temperatures of 42ºC suggesting that higher 
temperatures are required to produce hyperthermic effects in this cell line. The data 
illustrates the importance of radiant exposure on survival: increased radiant exposures 
resulted in decreased viability. For example, PCI spheroids (42ºC) exposed to 1 and 2.5 J 
cm
-2
 resulted in viabilities of 82 and 61%, respectively. The advantage of combining PCI 
+ HT is evident from the data. For example, overall viabilities for the PCI + HT and PCI 
(37
o
C) groups were 61 and 87%, respectively for a radiant exposure of 2.5 J cm
-2
. An 
alpha coefficient of 1.43 ± 0.04 at 30 days post-treatment indicates a synergistic effect 
between PCI and HT (42
o
C). The significant difference in viability between PDT + HT 












Figure 13. F98 spheroid viability as a function of days post-treatment. Each data point 
corresponds to the mean of three experiments (16 spheroids per experiment) and error 
bars denote standard errors.  
 
 
3.2 F98 Spheroid Growth Kinetics 
As illustrated in Figure 14, the growth kinetics of spheroids subjected to 42ºC 
were not statistically different from controls: HT treatment resulted in only a 5% 
reduction in volume at the conclusion of the 30-day observation period. The data 
presented in Figure 15 show that there were no statistically significant differences in 
growth kinetics between PDT and PCI at low radiant exposures. This is in good 
agreement with results obtained from human ACBT spheroids and therefore provides the 
rationale for using higher exposures in this cell line. A slight, but statistically significant 
PCI effect was observed beyond 19 days post-treatment (Figure 16). The data presented 
in Figure 17, show that the combined PCI + HT treatment produced a statistically 
significant growth delay compared to: (1) either treatment modality alone, and (2) PDT + 





temperature of 42 ºC resulted in a 31% reduction in size at 30 days versus control and 
HT-only and reductions of 26 and 28% compared to PCI-only and PDT+HT groups. 
 
Figure 14. Growth kinetics of F98 spheroids subjected to HT. Each data point represents 
the mean of three experiments and error bars denote standard errors. The HT effect was 



















Figure 15. Growth kinetics of F98 spheroids. Each data point corresponds to the mean of 
three experiments and error bars denote standard errors. The effects were not statistically 





Figure 16. Growth kinetics of F98 spheroids subjected to PDT and PCI at physiological 
temperatures. Each data point corresponds to the mean of three experiments and error 





Figure 17. Growth kinetics of F98 spheroids subjected to combination treatments. Each 
data point corresponds to the mean of three experiments and error bars denote standard 
errors. The effects were statistically significant, p < 0.01 and p < 0.001 for 37C PCI vs. 
42C PCI and 42C PDT vs. 42C PCI respectively.  
 
 
3.3 MCF-7 Spheroid Viability 
The MCF-7 spheroids elongated and became non-spheroidal at approximately 2.5 
weeks and measurements were therefore terminated. Greater cortical cell proliferation 
formed regionalized buds that lengthened in the spheroids.  Eventually this resulted in a 
luminal arrangement similar to those seen in breast glands (Amaral et al. 2010).  Figures 
18 and 19 show the process of spheroid formation with cortical budding and the 






Figure 18. MCF-7 spheroid formation. (Amaral et al. 2010) 
 
Figure 19. MCF-7 spheroid elongation. (Amaral et al. 2010) 
 
MCF-7 spheroid viability is shown in Figure 20. No cytotoxic effects were 
observed for spheroids exposed to temperatures of 42
o
C suggesting that higher 
temperatures are required to produce hyperthermic effects in this cell line. Increased 
radiant exposures resulted in decreased viability. For example, PCI spheroids (42
o
C) 
exposed to 1 and 2.5 J cm
-2
 resulted in viabilities of 97 and 82%, respectively. Again, the 
advantage of combining PCI + HT is evident from the data. For example, overall 
viabilities for the PCI + HT and PCI (37
o
C) groups were 82 and 93%, respectively. The 
calculated alpha coefficient 1.14 ± 0.01 indicates only a slight synergistic effect between 
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PCI and HT (42
o
C). In comparison, a higher degree of synergism was observed for the 
F98 spheroids (α = 1.31 ± 0.02 at 16 days). The significant difference in viability 
between PDT + HT and PCI + HT groups (98 vs. 82%) suggests that the observed effect 
was due to PCI.  
 
Figure 20. MCF-7 spheroid viability as a function of days post-treatment. Each data 
point corresponds to the mean of three experiments (16 spheroids per experiment) and 
error bars denote standard errors. 
 
3.4 MCF-7 Spheroid Growth Kinetics 
The degree of growth impairment of surviving MCF-7 spheroids was sensitively 
dependent on the treatment administered. As shown in Figure 21, temperatures of 42ºC 
did not result in statistically significant growth impairment. The data is in good 
agreement with those obtained for the F98 spheroids (Figure 14) and suggest that neither 
cell line is susceptible to HT at this temperature. Although a statistically significant 
difference in growth kinetics was observed between PDT and PCI groups at low radiant 
39 
 
exposures (Figure 22), the two exposures did not result in significant growth differences 
within either PDT- or PCI-exposed spheroids. The highest radiant exposure used (2.5 J 
cm
-2
) resulted in the greatest growth inhibition (Figure 23). This data also show a 
statistically significant difference in the growth kinetics of PCI and PDT treated 
spheroids at 37ºC. The effects of combined PCI and HT are illustrated in Figure 23. The 
PCI treatment at a radiant exposure of 2.5 J cm
-2
 resulted in a 25% reduction in size at 16 
days versus control. In comparison the HT treatment resulted in a 4% reduction in size 16 
days post-treatment (Figure 21).  The combined PCI+HT treatment at a radiant exposure 
of 2.5 J cm
-2 
and a temperature of 42 ºC resulted in a 31% reduction in size at 16 days 
versus control. A statistically significant difference between PCI + HT and PDT + HT 
combination treatments was observed. 
Figure 21. Growth kinetics of MCF-7 spheroids subjected to HT. Each data point 
represents the mean of three experiments and error bars denote standard errors. The HT 
effect was not statistically significant, p > 0.05. 
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Figure 22. Growth kinetics of MCF-7 spheroids. Each data point represents the mean of 
three experiments and error bars denote standard errors. The effects were statiscally 




Figure 23. Growth kinetics of MCF-7 Spheroids subjected to PDT and PCI at 
physiological temperatures. Each data point corresponds to the mean of three experiments 




Figure 24. Growth kinetics of MCF-7 spheroids subjected to combination treatments. 
Each data point represents the mean of three experiments and error bars denote standard 
errors. The effects were statistically significant, p < 0.05 and p < 0.01 for 37C PCI vs. 




























Photochemical internalization is a novel technology that is well documented and 
has been shown to enhance the effect of chemotherapeutics, cytotoxic targeting 
conjugates, gene-based therapeutics and nano-medicines by aiding the endosomal release 
of the macromolecule into the cytosol. Advantages of PCI include preferential 
accumulation of photosensitizers in malignant tissues, confinement of the treatment to 
tissues illuminated by light of a specific wavelength and the ability to deliver a wide 
range of macromolecules to specific targets. PCI has also been used to overcome induced 
drug resistance in therapeutic regimes and to avoid resistance mechanisms in multi-drug 
resistant (MDR) cancer cells (Selbo et al. 2006) 
 Clinical trials involving Amphinex-mediated PCI of bleomycin have shown 
complete clinical regression and high tumor to normal tissue specificity for patients with 
local recurrence of advanced/metastatic, cutaneous or sub-cutaneous malignancies (Selbo 
et al. 2010). This is most likely due to the accumulation of the photosensitizer in the 
endosomal membranes and the subsequent photochemical damage to those membranes 
releasing the sequestered bleomycin .  
The optimization of PCI involves several factors including: choice of 
photosensitizer and macromolecule, light irradiance and radiant exposure.  Different cell 
lines also have varying sensitivity to bleomycin. 
The parameters used in this study were previously optimized for the ACBT 
human glioma cell line. While both studies showed a synergistic effect for the combined 
PCI and HT treatment at 2.5 J cm
-2
 and 42ºC, a higher degree of synergism was observed 
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in the treatment of the ACBT spheroids. This is likely due to the fact that the treatment 
parameters were optimized for this cell line. The ACBT human glioma cells and F98 rat 
glioma cells reacted in a similar manner to low levels of radiant exposure (< 1.5 J cm
-2
) 
(Figure 15) while the MCF-7 spheroids varied in this respect (Figure 22). 
Comparing the relative damage from the PCI effect in the F98 and MCF-7 
spheroids we see a much larger PCI effect on the MCF-7 spheroids.  From the current 
experiments, the MCF-7 spheroids were observed to form larger periphery regions of 
proliferating cells.  Bleomycin studies have shown that the mechanism of DNA 
degradation is metal ion and oxygen dependent.  These dependencies result in greater 
cytotoxicity toward oxygenated cells compared with hypoxic cells (Teicher et al. 1981), 
thus causing a greater PCI effect in the MCF-7 spheroids due to a higher ratio of 
oxygenated cells to hypoxic cells. 
The relative damage from the HT effect was not statistically significant in either 
cell line.  The observed heat resistance is likely due to endogenous heat shock proteins 
(Hsp’s). Heat induces the accumulation of Hsp’s in the cytoplasm.  These proteins aid in 
the prevention of denaturation through various mechanisms including re-folding proteins 
that have undergone conformal changes. Research has shown that cells with higher 
expression of Hsp70 demonstrated increased cellular proliferation. This is probably due 
to the effective shortening of G0/G1 and S phases of the cell cycle by Hsp70 (Barnes et al. 
2001). The MCF-7 spheroids increased in size by a factor of 10 in approximately 9 days 
compared with the F98 spheroids which had a similar increase in approximately 23 days 
possibly indicating higher levels of Hsp70’s in the MCF-7 spheroids. 
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The combined PCI+HT treatment showed a similar percent volume reduction of 
approximately 31% for both the F98 and MCF-7 spheroids versus control. For both cell 
lines the treatment demonstrated a synergistic effect that is supported by previous studies. 
There are several processes that most likely contribute to this synergistic effect.  
First, when cells are subjected to hyperthermia it induces the accumulation of 
Hsp70’s. The accumulation of Hsp70’s allows the cell to continue to function by re-
folding heat damaged proteins. One particular protein that relates to this study is the 
Mre11 protein. Mre11 is a subunit of the MRN complex that is involved in signaling 
pathways for DNA double strand break (DSB) repair. This type of damage is produced 
by bleomycin. Hyperthermia denatures Mre11 proteins which then translocate from the 
nucleic region to the cytosol in an effort to associate with the Hsp70’s and re-fold 
(Dynlacht et al. 2011). Treatment with bleomycin and hyperthermia (40ºC) in murine L 
cells has been shown to suppress the accumulation of Hsp70’s by up to 38% compared to 
Hsp70’s levels induced by hyperthermia alone (Jin et al. 2002). In this situation the 
damaged Mre11 proteins are less readily repaired due to a suppression of Hsp70’s, and 
cannot initiate the DSB repair pathways. Thus, the cytotoxicity of the bleomcyin is 
enhanced by hyperthermia. 
Second, studies have shown that bleomycin treatments traditionally result in 
greater cytotoxicity to oxygenated cells compared to hypoxic cells. Teicher et al. have 
shown that this preferential cytotoxicity is absent in hyperthermic treatments (42-43ºC). 
Evidence supports that this non-preferential cytotoxicity is due to the ability of the 
bleomycin-iron complex to cleave DNA by an oxygen independent mechanism (Ajmera 
et al. 1986). It has also been proposed that the damage produced by the oxygen 
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independent mechanism is normally repaired at standard temperatures but becomes fixed 
by the heat treatment (Meyn et al. 1979). 
Lastly, as discussed earlier, hyperthermia denatures the bleomycin hydrolase 
enzyme hindering the bleomycin inactivation ability of the cell.   
The reduced ability of the cells to repair DSB’s and the heat–induced damage 
fixation and resistance reduction likely work in concert to produce the observed 
synergistic effect. 
This is evidenced by the present results.  The combined treatments resulted in a 
higher degree of synergism at 16 days for the F98 spheroids (alpha coefficient of 1.31 ± 
0.02 compared to 1.14 ± 0.01 for the MCF-7 spheroids). With a smaller ratio of 
oxygenated to hypoxic cells the F98 spheroids showed a smaller PCI effect while the 
MCF-7 spheroids with a larger ratio of oxygenated to hypoxic cells, exhibited a larger 
PCI effect due to the preferential cytotoxicity towards oxygenated cells at standard 
temperatures.  When the temperature was increased to 42ºC the preferential cytotoxicity 
disappeared and both F98 and MCF-7 spheroids exhibited a similar effect. 
Although the combined PCI+HT treatment had an overall similar effect on the 
F98 and MCF-7 spheroids, the proliferation gradient likely affected the extent and 
mechanism of the damage from the individual treatments. 
 











 The overall objective of this work was to investigate the effect of a combined PCI 
and HT treatment on multicellular spheroids of two different cell lines.  The hyperthermic 
treatment (42ºC) showed no decrease in spheroid viability for either cell line. There were 
no significant differences between PCI and PDT treatments at physiological temperatures 
and radiant exposures < 1.5 J cm
-2
 for F98 rat glioma spheroids.  This is in agreement 
with the previous study of ACBT human glioma spheroids. The MCF-7 spheroids, 
however, showed a significant difference between PCI and PDT treatments at 
physiological and hyperthermic temperatures (37 and 42ºC) for all radiant exposures (1, 
1.5 and 2.5 Jcm
-2
). The combined PCI and HT effect was shown to be statistically 
significant and synergistic for both cell lines, with a greater degree of synergism present 
in the F98 cell line (alpha coefficient of 1.42 ± 0.04 vs. 1.14 ± 0.01).   
 Further studies can be performed to better understand the processes that result in 
the observed synergism. Experiments that investigate the accumulation of Hsp’s and 
bleomycin hydrolase specific to these cell lines could lead to a better understanding of 
their resistances. With a better understanding of the underlying mechanisms, treatment 
parameters can then be optimized to the specific cell resulting in the greatest tumor 
control. In vivo studies can be performed to evaluate the effectiveness of the treatment 
and understand the effects of vasculature on the treatment. Treatment sequence is another 
area of possible exploration for these specific cell lines. Sequence optimization could be 
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performed by investigating the differences in cytotoxic effects of “light first” PCI vs. 
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